1. All Products
  2. D - Drugs
  3. AS 60mg/ PYRONARIDINE 180mg, tab.
Public Pricelist

AS 60mg/ PYRONARIDINE 180mg, tab.

https://medicalguidelines.msf.org/en/node/1024
https://unicat.msf.org/cat/product/74499
STD DORAASPY1T1

Valid Article

6.5.3.1 - Medicines for curative treatment
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01BF06
Anatomical Therapeutic Chemical Classification according to WHOCC
PM
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/589767/image_1920?unique=9554a50

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

ARTESUNATE / PYRONARIDINE - NST

Full Name

Pyramax®

Therapeutic Action

Fixed-dose combination (FDC) of two antimalarials: pyronaridine tetraphopshate in combination with artesunate (artemisine derivative).

Indications

Uncomplicated malaria, caused by Plasmodium falciparum or Plasmodium vivax in emergency settings, including:

  • Intermittent Preventive Therapy (IPTc) in children
  • seasonal chemoprevention, in non SPAQ setting where Artemisinin Combinations Therapy (ACT) is preferred
  • mass targeted drug administration

First-choice ACT for the management of malaria in patients with VHF (including Ebola, Marburg, Lassa, and other VHFs), as well as for preventive/prophylactic therapy in known exposed contacts of Ebola/VHF patients.

Artesunate/Pyronaridine is already registered in some countries. Follow the national protocol.

Not indicated for:

Some restricted information has been hidden. Sign in to see this information

Instructions for use

2 different presentations for 2 categories of weight:

  • DORAASPY1T1: tablet intended for adults and children > 20 kg
  • DORAASPY1S1: sachet of granules for oral solution intended for children and infants between 5-20 kg

Both presentations must be ordered for both weight categories.

Posology:

Single daily dose for three consecutive days.

Administer dose based on body weight:

Body weightNumber of tablets/sachetsRegimen
5 - < 8 kg1 sachetdaily for 3 days
8 - < 15 kg2 sachetsdaily for 3 days
15 - < 20 kg3 sachetsdaily for 3 days
20 - < 24 kg1 tabletdaily for 3 days
24 - < 45 kg2 tabletsdaily for 3 days
45 - < 65 kg3 tabletsdaily for 3 days
≥ 65 kg4 tabletsdaily for 3 days

Administration:

  • Granules: Mix the contents of the required sachets in approximately 10 ml (2 teaspoons) of water. Stir gently to suspend the granules (they will not dissolve). The child should swallow the suspension immediately. Add an additional 10 ml of water to the cup, mix in the remaining granules, and administer to the child again. Repeat until all the granules have been consumed.
  • Tablets are to be swallowed whole.
Image

Precautions for Use

Do not administer in patients with severe malaria, cardiac, kidney or liver impairment.

Contraindicated during the first trimester of pregnancy and during breastfeeding.

Storage

Below 25°C - Protect from sunlight